Phase I Study of TK216 in Patients With Relapsed and Refractory Leukemias
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 08 May 2019
Price : $35 *
At a glance
- Drugs TK 216 (Primary) ; Decitabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 02 May 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 21 Nov 2018 Status changed from planning to not yet recruiting.
- 07 Sep 2017 New trial record